MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$146.53
+1.29%Year over year
Reported trailing growth
- Revenue
- +4.8%
- EBITDA
- -52.9%
- EBIT
- -56.1%
- EPS
- -87.1%
- Free cash flow
- -5.3%
- Operating cash flow
- -3.5%
Forward estimates
Based on analyst estimates
- Revenue
- +1.0%
- EBITDA
- +167.8%
- EPS
- +767.0%
Three-year CAGR
- Revenue
- +3.1%
- EBITDA
- +9.9%
- EBIT
- +8.7%
- Net income
- +7.9%
- EPS
- +8.4%
- Free cash flow
- -5.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026